Description
Report Code: PHP12774. April, 2012 . Toronto, ON
Article 1
Breaking Issues in Canadian Drug Reimbursement
Bob Kamino
President
The Canadian Association for Healthcare Reimbursement
Article 2
CADTH’s Common Drug Review: Addressing Emerging Challenges
in a Changing Therapeutic Landscape
Matthew Brougham
Vice President, Products and Services
Canadian Agency for Drugs and Technologies in Health (CADTH)
Article 3
Government Trends in the Pharmaceutical Industry
Mark Ferdinand
Senior Director, Health and Economic Policy
Canada’s Research-Based Pharmaceutical Companies (Rx&D)
Article 4
Pricing & Reimbursement Dynamics in Europe
W. Neil Palmer
President & Principal Consultant
PDCI Market Access
Article 5
Alberta PLA Update: Spring 2012
Filip Palasz
Senior Manager
Pharmaceutical Funding and Guidance Branch
Alberta Health and Wellness
Article 6
Product Listing Agreements: Provincial Innovations and Developments
Alan West
Partner, Life Sciences
Gowlings LLP
Article 7
Pan Canadian Oncology Drug Review (p-CODR)
Dr. Judith L. Glennie
President
J.L. Glennie Consulting Inc.
Article 8
Quebec Updates and New Developments – INESSS One Year Later
France Mignault
Director, Government Affairs
JANSSEN Inc.
Rx&D INESSS Committee Lead
Article 9
The Case for a Canadian Orphan Drugs Policy
Kelly Gorman
Program Director, Advocacy & Public Policy
Cystic Fibrosis Canada
Board Member
Canadian Organization for Rare Disorders (CORD)
Article 10
Orphan Drugs – Meeting Regulatory and Reimbursement Challenges
Alan West
Partner, Life Sciences
Gowlings LLP
Article 11
Regulatory Approach for Subsequent Entry Biologics (Biosimilars)
in Canada: Emerging Directions and Challenges
Kwasi A. Nyarko, PhD
Regulatory Science Advisor
Office of Policy and International Collaboration, Biologics
and Genetic Therapies Directorate, Health Canada
Article 12
Links Between Clinical Research, Market Access and
Drug Pricing
Dr. David Griller
Partner
SECOR Consulting
Article 13
NOC/C and Reimbursement Interface
Anne Tomalin
Strategic Regulatory and Safety
OptumInsight
Article 14
Private Drug Plans – Progress and Current Challenges
Suzanne Lepage
Private Health Plan Strategist
Suzanne Lepage Consulting
Article 15
Private Drug Plans – Progress and Current Challenges
Barbara Martinez
Principal
Mercer
Article 16
Patented Medicine Prices Review Board (PMPRB)
W. Neil Palmer
President & Principal Consultant
PDCI Market Access
Article 17
Risk Sharing Agreements – Impact, Opportunities, Concerns
Alain Boisvert, M.Sc (Pharm.)
Vice President, Market Access
Bristol-Myers Squibb Canada
Article 18
Risk Sharing Agreements – Impact, Opportunities, Concerns
Dr. Judith L. Glennie
President
J.L. Glennie Consulting Inc.
Article 19
Everybody Wins! Using Innovation to Drive a Successful Path
from Clinical to Regulatory to Commercial to Payers to Patients
George Wyatt, B.Sc., MBA
Managing Director
Wyatt Health Management
Article 20
Potential Reform for Pharmaceuticals: The Case for
a National Universal Pharmacare
Marc-André Gagnon, PhD
Assistant Professor, School of Public Policy and Administration
Carleton University
Article 21
An Action Items for Life Sciences Stakeholders
Steve Sampson
Director, Health and Life Sciences
Global Public Affairs
Article 22
Action Items for Canada’s Life Sciences Stakeholders
and Regulators
Dr. Judith L. Glennie
President
J.L. Glennie Consulting Inc.